Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4):279-88

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REVIEWS  RADIOIMMUNOTHERAPY
Guest Editor: S. J. Mather
FREEfree


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4):279-88

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Engineered single chain antibody fragments for radioimmunotherapy

Huhalov A., Chester K. A.

Cancer Research UK Imaging and Targeting Group Department of Oncology, Royal Free and University College Medical School, Royal Free Campus London, United Kingdom


FULL TEXT  


An ideal molecule to deliver radioimmunotherapy (RIT) would be target specific and have prolonged residence time at high concentrations in the tumour with rapid clearance from normal tissues. It would also be non-immunogenic. These features can be rationally introduced into recombinant antibody-based proteins using antibody engineering techniques. This review focuses on the use of antibody engineering in the design and development of RIT molecules which have single chain Fv (scFv) antibody fragments as building blocks.

top of page

Publication History

Cite this article as

Corresponding author e-mail